IDEXX Laboratories (IDXX) stock
IDXX · IDEXX Laboratories Inc. · NASDAQ
- Market cap
- $54.33B
- EPS (TTM)
- $14.84
- Shares out
- 78.8M
Why is IDXX stock moving today?
4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
All IDXX newsWhen does IDEXX Laboratories report earnings?
IDEXX Laboratories last reported on Nov 2, 2026, the date it announced on Oct 1, 2026. Before that it reported on Aug 4, 2026 and May 5, 2026. On that schedule the next report would come around early February 2027, with the date usually announced about 4 weeks ahead.
IDXX earnings historyWho owns the most IDXX stock?
BlackRock, Inc. was the largest reported holder of IDXX at the end of Q2 2026, with 8,170,178 shares worth $4.3 billion. Next came Vanguard Capital Management LLC ($2.7 billion) and Vanguard Portfolio Management LLC ($2.1 billion). In all, 1,300 institutions reported $39.2 billion of IDXX in their 13F filings.
All IDXX fund holdersAre insiders buying or selling IDXX?
Insiders are selling. In the last 90 days 5 insiders sold $28.6 million of IDXX in trades reported on Form 4. The latest: Sharon E. Underberg sold $6.1 million, reported on Nov 5, 2026.
IDXX insider tradesFinancial highlights
Full financials- Revenue, TTM
- $4.66B
- Revenue growth
- +11.9%
- Net income, TTM
- $1.18B
- Net margin
- 25.4%
- Free cash flow, TTM
- $1.30B
- Cash
- $197.54M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
Latest news
25 items- INSIDERExecutive Chair of the Board Jonathan Jay Mazelsky gifted 700 shares, decreasing direct ownership by 0.84% to 83,103 units (SEC Form 4)4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- INSIDERExecutive Vice President Fennell George exercised 1,749 shares at a strike of $171.38, increasing direct ownership by 17% to 12,182 units (SEC Form 4)4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- INSIDEREVP, GC & Corporate Secretary Underberg Sharon E. exercised 8,906 shares at a strike of $288.78 and sold $6,132,605 worth of shares (8,906 units at $688.59) (SEC Form 4)4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- INSIDERExecutive Vice President Lane Michael sold $2,740,069 worth of shares (3,979 units at $688.64), decreasing direct ownership by 49% to 4,076 units (SEC Form 4)4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- INSIDERExecutive Chair of the Board Mazelsky Jonathan Jay exercised 25,140 shares at a strike of $178.26 and sold $17,678,195 worth of shares (25,140 units at $703.19) (SEC Form 4)4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- INSIDERDirector Junius Daniel M sold $844,888 worth of shares (1,200 units at $704.07), decreasing direct ownership by 34% to 2,361 units (SEC Form 4)4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- INSIDERDirector Hooley Joseph L was granted 48 shares, increasing direct ownership by 15% to 373 units (SEC Form 4)4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- SECSEC Form 10-Q filed by IDEXX Laboratories Inc.10-Q - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
- SECIDEXX Laboratories Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
- PRIDEXX Laboratories Announces Third Quarter ResultsAchieves third quarter revenue growth of 10% as reported and organic and CAG Diagnostics recurring revenue growth of 11% as reported and organic. Double-digit organic revenue growth was led by strong volume expansion, including benefits from IDEXX's innovations and excellent commercial execution. Places over 1,900 IDEXX inVue Dx™ analyzers during the quarter, driving installed base to nearly 11,000 instruments. Delivers EPS of $4.01, an increase of 18% as reported and 22% on a comparable basis, with operating margin up 100 basis points as reported and 60 basis points on a comparable basis. Increases 2026 revenue guidance to $4,741 million - $4,767 million, up $32 million at mid
- ANALYSTGoldman initiated coverage on IDEXX Labs with a new price targetGoldman initiated coverage of IDEXX Labs with a rating of Buy and set a new price target of $740.00
- ANALYSTKeyBanc Capital Markets initiated coverage on IDEXX LabsKeyBanc Capital Markets initiated coverage of IDEXX Labs with a rating of Sector Weight
- PRIDEXX Laboratories to Release 2026 Third Quarter Financial ResultsIDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 third quarter financial results for Monday, November 2, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q3 2026 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen
- PRChicago Pacific Founders Pet Fund Announces Exit of CoVetAI Following Acquisition by IDEXX LaboratoriesTransaction marks the first realization from the now closed specialist animal health fund's inaugural vehicleCHICAGO, Sept. 30, 2026 /PRNewswire/ -- Chicago Pacific Founders ("CPF") today announced the exit of its investment in CoVetAI Inc. ("CoVet") following the company's acquisition by IDEXX Laboratories, Inc. (NASDAQ:IDXX). Financial terms were not disclosed.Transaction OverviewCoVet, developer of an AI-powered clinical scribe and workflow platform for veterinary medicine, was a high-conviction investment aligned with the CPF's focus on category-defining companies in veterinary technology and pet wellness. CPF was the sole institutional investor in CoVet.IDEXX's acquisition underscores C
- PRIDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm DetectionExpanded testing menu now detects more intestinal parasites during routine visits IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the expansion of its Faecal Dx™ antigen testing platform in the United Kingdom with taeniid tapeworm, including Taenia and Echinococcus species. Proven to detect up to twice as many intestinal parasite infections earlier than faecal flotation alone,1 Faecal Dx antigen testing delivers broader parasite detection in a single test for both wellness and sick-pet care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260917879004/en/IDEXX Faecal Dx™ ant
- PRIDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow IntelligenceAcquisition strengthens IDEXX’s connected diagnostic and software ecosystem with AI-native workflow capabilities that enhance efficiency, clinical decision-making, and diagnostic utilization IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the acquisition of CoVetAI Inc. (CoVet), a leading and rapidly growing provider of AI-native ambient listening and clinical workflow software for veterinary practices. Serving both multipractice corporate groups and independent veterinary practices worldwide, CoVet helps veterinary teams automatically capture and organize information across the patient care journey, from consultation to treatment plan
- INSIDERDirector Kingsley Lawrence D exercised 2,203 shares at a strike of $114.17 and sold $1,172,178 worth of shares (2,203 units at $532.08) (SEC Form 4)4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- PRIDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare ConferenceIDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, and Andrew Emerson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, from 10:45 am – 11:20 am (ET). A live audio webcast of the fireside chat will be available through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the fireside chat will be available via the same link. About IDEXX Laboratories, Inc. IDEXX is a global leader in pet healthcare innovation. Our diagnos
- INSIDEREVP, CFO and Treasurer Emerson Andrew exercised 265 shares at a strike of $178.26 and covered exercise/tax liability with 86 shares, increasing direct ownership by 4% to 4,421 units (SEC Form 4)4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- PRIDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP TestNew test brings quantitative cardiac assessment for cats and dogs into everyday workflows IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the launch of the Catalyst™ proBNP Test, the first and only dual-species, in-clinic test for NT-proBNP, expanding cardiac capabilities across its connected point-of-care and reference laboratory portfolio. The test measures a well-established biomarker used to evaluate heart disease in companion animals, a condition that affects approximately 1 in 6 cats1 and 1 in 10 dogs2, yet remains underassessed in general practice. Available on the Catalyst platform with a global installed base of nearly 80,000
- SECSEC Form 10-Q filed by IDEXX Laboratories Inc.10-Q - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
- SECIDEXX Laboratories Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
- PRIDEXX Laboratories Announces Second Quarter ResultsAchieves second quarter revenue growth of 10% as reported and 9% organic, and CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic. Strong volume-driven CAG Diagnostics recurring revenue growth including benefits from IDEXX's innovations and expansion of diagnostics utilization. IDEXX inVue Dx™ installed base surpasses 9,000 instruments, supported by over 1,600 placements during the quarter. Drives EPS of $4.27, an increase of 18% as reported and 15% on a comparable basis, with operating margin up 140 basis points as reported and 110 basis points on a comparable basis. Narrows 2026 revenue guidance to $4,700 million - $4,745 million, up $5 million at midp
- INSIDERDirector Hooley Joseph L was granted 49 shares, increasing direct ownership by 18% to 325 units (SEC Form 4)4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
- PRIDEXX Releases 2025 Corporate Responsibility Report, Highlighting Progress Against Its GoalsIDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today released its 2025 Corporate Responsibility Report, highlighting progress against the company’s goals and commitments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260728755319/en/2025 IDEXX Corporate Responsibility Report "At IDEXX, corporate responsibility is central to how we create long-term value," said Mike Erickson, IDEXX President and Chief Executive Officer. "The progress reflected in this report is the result of sustained investments in innovation, our people, and capabilities that support our customers every day. These priorit
Hiring
Nov 20, 2026IDEXX Laboratories Inc. lists 229 open roles on its careers site as of Nov 20, 2026.
- Open roles
- 229
Counted daily from IDEXX Laboratories Inc.'s careers site.
IDXX rankings
- Insider9(47%)
- Other3(16%)
- Earnings2(11%)
- Analyst2(11%)
- SEC Filings2(11%)
- M&A1(5%)
Our reporting on IDXX
- IDEXX jumps 22% as investors pay up for testing growth that outruns clinic trafficResearch · Nov 2, 2026 · 7 min read

- IDEXX beats Q3 EPS by about 8% and raises its guide by $0.25, a smaller step than the $0.30 beat, while LITX is the lone unexplained pre-market moverPre-market brief · Nov 2, 2026 · 7 min read

IDEXX Laboratories Inc. (IDXX) is a Biotechnology: In Vitro & In Vivo Diagnostic Substances company listed on NASDAQ. In the last 30 days Quantisnow tracked 10 wire items for IDXX, including 7 insider trades, 2 SEC filings and 1 earnings update. The most recent was published Nov 18, 2026.
IDXX FAQ
11 questionsWhat does IDEXX Laboratories Inc. do?
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health...What is IDXX revenue?
IDEXX Laboratories Inc. (IDXX) reported $4.66B of revenue for the twelve months ended Sep 30, 2026. That is up 11.9% from the year before. Revenue for fiscal 2025 was $4.30B.Is IDXX profitable?
Yes. IDEXX Laboratories Inc. earned $1.18B in net income for the twelve months ended Sep 30, 2026, a net margin of 25.4%.How much cash and debt does IDXX have?
IDEXX Laboratories Inc. reported $197.54M in cash and cash equivalents and $374.88M of debt on its most recent balance sheet in SEC filings.Is IDEXX Laboratories Inc. (IDXX) hiring?
IDEXX Laboratories Inc. lists 229 open roles on its careers site as of Nov 20, 2026.Where does IDXX stock trade?
IDEXX Laboratories Inc. (IDXX) is listed on NASDAQ.What sector and industry is IDXX in?
IDEXX Laboratories Inc. operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.When did IDEXX Laboratories Inc. go public?
IDEXX Laboratories Inc. (IDXX) completed its IPO in 1991.What are analysts saying about IDXX?
Across the last 8 analyst actions on IDEXX Laboratories Inc., there was 1 upgrade and 0 downgrades. The most recent action was from Goldman: Buy with a $740.00 price target on 2026-10-16. Recent price targets range from $625.00 to $850.00.What companies are similar to IDXX?
Notable peers in the same industry include ZTS (Zoetis Inc.), ELAN (Elanco Animal Health Incorporated), TMO (Thermo Fisher Scientific Inc), NEOG (Neogen Corporation). Compare IDXX side-by-side with any of them on Quantisnow.How can I track IDXX on Quantisnow?
Quantisnow aggregates IDEXX Laboratories Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IDXX to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change